{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:04:38Z","timestamp":1790395478932,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ymgme.2023.107692","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:53:25Z","timestamp":1693356805000},"page":"107692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Screening for health-related quality of life and its determinants in Fabry disease: A cross-sectional multicenter study"],"prefix":"10.1016","volume":"140","author":[{"given":"Yaroslav","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Hilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsukimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Hennermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2023.107692_bb0005","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"Eng CM: \u03b1-galactosidase a deficiency: Fabry disease","author":"Desnick","year":"2014"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107692_bb0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107692_bb0015","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of classical and nonclassical Fabry disease: a multicenter study","volume":"28","author":"Arends","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107692_bb0020","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1007\/s12325-019-01061-x","article-title":"Symptoms and quality of life in patients with Fabry disease: results from an international patient survey","volume":"36","author":"Morand","year":"2019","journal-title":"Adv. Ther."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107692_bb0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry\u2019s disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107692_bb0030","doi-asserted-by":"crossref","first-page":"103703","DOI":"10.1016\/j.ejmg.2019.103703","article-title":"Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males","volume":"63","author":"Oliveira","year":"2020","journal-title":"Eur. J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107692_bb0035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107692_bb0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107692_bb0045","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","article-title":"Characterization of pain in fabry disease","volume":"30","author":"Uceyler","year":"2014","journal-title":"Clin. J. Pain"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107692_bb0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000226792","article-title":"Excessive daytime sleepiness is a common symptom in Fabry disease","volume":"1","author":"Duning","year":"2009","journal-title":"Case Rep. Neurol."},{"key":"10.1016\/j.ymgme.2023.107692_bb0055","article-title":"Depression, sleep disturbances, pain, disability and quality of LIFE in Brazilian Fabry disease patients","volume":"22","author":"Rosa Neto","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107692_bb0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11325-019-01832-4","article-title":"Obstructive sleep apnea and quality of life in Fabry disease: a prospective parallel cohort study","volume":"24","author":"Gaisl","year":"2020","journal-title":"Sleep Breath."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107692_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225071","article-title":"Significant hearing loss in Fabry disease: study of the Danish nationwide cohort prior to treatment","volume":"14","author":"Yazdanfard","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107692_bb0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","article-title":"Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study","volume":"41","author":"Arends","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107692_bb0075","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and later-onset Fabry disease","volume":"121","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.107692_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107692_bb0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107692_bb0090","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","volume":"59","author":"Nowak","year":"2022","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107692_bb0095","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jimd.12167","article-title":"Fabry disease genotype, phenotype, and migalastat amenability: insights from a national cohort","volume":"43","author":"Nowak","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107692_bb0100","first-page":"377","article-title":"Mitral valve replacement in post-infarction rupture of the papillary muscle. Apropos of 13 cases surgically treated during the acute phase of infarction","volume":"83","author":"Defraigne","year":"1990","journal-title":"Arch. Mal. Coeur Vaiss."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107692_bb0105","first-page":"169","article-title":"Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire","volume":"2","author":"Brazier","year":"1993","journal-title":"Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehab."},{"key":"10.1016\/j.ymgme.2023.107692_bb0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107692_bb0115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10198-003-0182-5","article-title":"A single European currency for EQ-5D health states. Results from a six-country study","volume":"4","author":"Greiner","year":"2003","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.ymgme.2023.107692_bb0120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. Gen. Psychiatry"},{"issue":"15","key":"10.1016\/j.ymgme.2023.107692_bb0125","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/jnci\/80.15.1198","article-title":"Regression-models in clinical-studies - determining relationships between predictors and response","volume":"80","author":"Harrell","year":"1988","journal-title":"J. Natl. Cancer I"},{"issue":"4","key":"10.1016\/j.ymgme.2023.107692_bb0130","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","article-title":"Quality of life of patients with Fabry disease","volume":"11","author":"Gold","year":"2002","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ymgme.2023.107692_bb0135","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1471-2369-15-188","article-title":"Kidney function as an underestimated factor for reduced health related quality of life in patients with Fabry disease","volume":"15","author":"Wagner","year":"2014","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ymgme.2023.107692_bb0140","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.yebeh.2017.12.037","article-title":"Health-related quality of life in patients with poststroke epilepsy","volume":"80","author":"Winter","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107692_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105129","article-title":"Quality of life and resilience of patients with juvenile stroke: a systematic review","volume":"29","author":"Bartholome","year":"2020","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.107692_bb0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2010.04.011","article-title":"Trends in resource utilization for Parkinson\u2019s disease in Germany","volume":"294","author":"Winter","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107692_bb0155","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107692_bb0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijcard.2017.09.027","article-title":"Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up","volume":"249","author":"Siegenthaler","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107692_bb0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International collaborative Fabry disease study G: safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107692_bb0170","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s disease with the pharmacologic chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107692_bb0175","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","article-title":"Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy","volume":"62","author":"Hilz","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107692_bb0180","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","article-title":"Investigators FOSE: effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry outcome survey)","volume":"42","author":"Hoffmann","year":"2005","journal-title":"J. Med. Genet."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107692_bb0185","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/cns.12542","article-title":"Pain in Fabry disease: practical recommendations for diagnosis and treatment","volume":"22","author":"Politei","year":"2016","journal-title":"CNS Neurosci. Ther."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107692_bb0190","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00415-012-6619-y","article-title":"FabryScan: a screening tool for early detection of Fabry disease","volume":"259","author":"Arning","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2023.107692_bb0195","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1477-7525-10-116","article-title":"Measuring patient experiences in Fabry disease: validation of the Fabry-specific pediatric health and pain questionnaire (FPHPQ)","volume":"10","author":"Ramaswami","year":"2012","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.ymgme.2023.107692_bb0200","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13023-015-0325-7","article-title":"Self-administered version of the Fabry-associated pain questionnaire for adult patients","volume":"10","author":"Magg","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107692_bb0205","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cge.12673","article-title":"Gastrointestinal involvement in Fabry disease. So important, yet often neglected","volume":"89","author":"Politei","year":"2016","journal-title":"Clin. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107692_bb0210","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1053\/j.gastro.2020.06.007","article-title":"Effects of orally delivered alpha-galactosidase a on gastrointestinal symptoms in patients with Fabry disease","volume":"159","author":"Lenders","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107692_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106913","article-title":"Characterizing the individual course of health-related quality of life after subarachnoid haemorrhage: latent growth mixture modelling","volume":"32","author":"Winter","year":"2023","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107692_bb0220","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1159\/000325829","article-title":"Health-related quality of life in multiple system atrophy and progressive supranuclear palsy","volume":"8","author":"Winter","year":"2011","journal-title":"Neurodegener. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107692_bb0225","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00415-013-6831-4","article-title":"Neuroborreliosis-associated cerebral vasculitis: long-term outcome and health-related quality of life","volume":"260","author":"Back","year":"2013","journal-title":"J. Neurol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223003220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223003220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T17:14:28Z","timestamp":1735233268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223003220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1096719223003220"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107692","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for health-related quality of life and its determinants in Fabry disease: A cross-sectional multicenter study","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107692","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107692"}}